Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The reporting period covers the month of April 2025, with the specific transaction date being April 4, 2025. The filing serves as a disclosure of share repurchases executed under an existing buyback programme.
Key Financial Metrics and Transaction Details
The filing details a specific block of share repurchases rather than providing comprehensive financial statements (revenue, profit, or cash flow are not included in this document).
- Shares Purchased: 808,000 ordinary shares of 31½ pence each.
- Trading Venue: London Stock Exchange (XLON).
- Price Range: Lowest price paid was 1,413.00p; highest price paid was 1,468.50p.
- Volume-Weighted Average Price (VWAP): 1,436.14p.
- Broker: Citigroup Global Markets Limited.
- Treasury Shares Held: Following this purchase, GSK holds 190,303,940 ordinary shares in treasury.
- Shares in Issue: 4,124,923,142 ordinary shares (excluding Treasury shares).
- Total Voting Rights: 4,124,923,142.
Material Changes and Programme Progress
This purchase is part of a non-discretionary agreement entered into with the broker on February 24, 2025. Since the inception of this specific agreement on February 24, 2025, the Company has purchased a total of 21,233,637 ordinary shares. The filing does not provide comparative financial data against prior periods as it is a transactional disclosure.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced as being described on pages 277 to 285 of the GSK 2024 Annual Report on Form 20-F. No new guidance or management commentary regarding operational outlook is provided in this specific filing.
Important Facts for Investor Verification
- Verify the total number of treasury shares held (190,303,940) against the company's latest capital structure disclosures.
- Confirm the remaining authorization under the buyback programme initiated on February 24, 2025, to assess future repurchase capacity.
- Note that the VWAP of 1,436.14p reflects the execution price for this specific block of 808,000 shares.
- Review the referenced GSK 2024 Annual Report on Form 20-F (pages 277-285) for detailed risk factors associated with the company's operations and financial projections.